Building rendering of a new, state-of-the-art science and innovation heart at Amgen’s international headquarters in Thousand Oaks, California.
Courtesy: Amgen
Amgen on Tuesday stated it’ll spend greater than $600 million to construct a new analysis and growth facility at its headquarters in Thousand Oaks, California, the newest in a string of new U.S. investments by the pharmaceutical trade.
Drugmakers have been scrambling to increase their presence in the U.S. as President Donald Trump threatens to clamp down on the trade with tariffs on pharmaceuticals imported into the nation. Trump has stated these levies will incentivize corporations to re-shore manufacturing at a time when home drug manufacturing has shrunk dramatically over the previous decade.
In a launch, Amgen stated development of the facility will start in the third quarter of this 12 months and can create lots of of U.S. jobs.
Notably, the facility isn’t a producing plant, however it’ll enable researchers, engineers and scientists to collaborate on discovering next-generation medication for sufferers with “the most serious diseases,” in accordance to the corporate. Amgen stated the constructing options “advanced automation and digital capabilities,” which can give scientists the required instruments for that analysis and growth.
“At Amgen, we’re continuing to invest in the future of American science and innovation,” CEO Bob Bradway stated in the discharge. “The center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health.”
Amgen stated that for the reason that passage of the Tax Cuts and Jobs Act of 2017, it has invested nearly $5 billion in direct U.S. capital expenditures. In April, the corporate introduced a $900 million enlargement of its Ohio biotech manufacturing facility. In December, the drugmaker introduced it will spend $1 billion to construct a second drug substance plant in Holly Springs, North Carolina.
Those investments come after the U.S. Food and Drug Administration in August launched a program that goals to make it simpler for corporations to arrange new drug manufacturing vegetation in the U.S. The White House estimates it could actually presently take 5 to 10 years to construct new manufacturing capability for prescription drugs, which it previously called “unacceptable from a national-security standpoint.”